NCT04603183: Abemaciclib, Endocrine Therapy ± Paclitaxel in Aggressive Hormone Receptor (HR)[+]/Human Epidermal Growth Factor Receptor 2 (HER2)[-] Metastatic Breast Cancer (MBC) Trial

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known active progressive brain metastases – see trial for details; Patients with leptomeningeal disease; Patients with prior systemic therapy for metastatic disease

Comments are closed.

Up ↑